|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.44 | 89.46 | 104.56 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
416.95
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | 15.34 | 16.77 | 10.03 | 2.63 | -0.31 | CEPS(Rs) | 23.00 | 25.34 | 17.96 | 10.32 | 7.46 | DPS(Rs) | 2.25 | 2.25 | 1.50 | 0.30 | 0.30 | Book NAV/Share(Rs) | 111.38 | 98.13 | 83.44 | 73.81 | 71.74 | Tax Rate(%) | 26.22 | 34.59 | 29.66 | 15.54 | 69.26 | Margin Ratios | | | | | | Core EBITDA Margin(%) | 17.09 | 21.17 | 17.55 | 10.94 | 7.93 | EBIT Margin(%) | 13.01 | 16.47 | 12.38 | 4.97 | 1.22 | Pre Tax Margin(%) | 11.50 | 15.34 | 10.59 | 2.60 | -0.96 | PAT Margin (%) | 8.48 | 10.04 | 7.45 | 2.19 | -0.29 | Cash Profit Margin (%) | 12.72 | 15.16 | 13.34 | 8.59 | 7.10 | Performance Ratios | | | | | | ROA(%) | 8.58 | 10.60 | 7.17 | 1.97 | -0.23 | ROE(%) | 14.64 | 18.47 | 12.75 | 3.62 | -0.43 | ROCE(%) | 17.42 | 23.31 | 15.59 | 5.79 | 1.24 | Asset Turnover(x) | 1.01 | 1.06 | 0.96 | 0.90 | 0.79 | Sales/Fixed Asset(x) | 1.26 | 1.28 | 1.08 | 1.07 | 1.06 | Working Capital/Sales(x) | 4.39 | 4.45 | 5.81 | 10.78 | 10.61 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 0.79 | 0.78 | 0.93 | 0.93 | 0.94 | Receivable days | 70.94 | 62.89 | 65.15 | 66.60 | 75.87 | Inventory Days | 69.70 | 64.99 | 65.63 | 64.62 | 71.02 | Payable days | 91.64 | 100.02 | 145.00 | 186.13 | 182.48 | Valuation Parameters | | | | | | PER(x) | 21.22 | 22.46 | 28.77 | 79.56 | 0.00 | PCE(x) | 14.15 | 14.86 | 16.06 | 20.29 | 27.18 | Price/Book(x) | 2.92 | 3.84 | 3.46 | 2.84 | 2.83 | Yield(%) | 0.69 | 0.60 | 0.52 | 0.14 | 0.15 | EV/Net Sales(x) | 1.98 | 2.40 | 2.34 | 1.95 | 2.20 | EV/Core EBITDA(x) | 11.49 | 11.11 | 12.81 | 17.12 | 25.51 | EV/EBIT(x) | 15.23 | 14.57 | 18.91 | 39.18 | 179.62 | EV/CE(x) | 1.93 | 3.22 | 2.82 | 1.74 | 1.74 | M Cap / Sales | 1.80 | 2.25 | 2.14 | 1.74 | 1.93 | Growth Ratio | | | | | | Net Sales Growth(%) | 8.25 | 24.14 | 12.14 | 14.29 | -6.79 | Core EBITDA Growth(%) | -13.57 | 46.73 | 80.24 | 50.78 | -40.27 | EBIT Growth(%) | -14.51 | 65.18 | 179.41 | 363.91 | -83.53 | PAT Growth(%) | -8.52 | 67.25 | 281.03 | 953.48 | -106.90 | EPS Growth(%) | -8.52 | 67.25 | 281.02 | 953.52 | -106.90 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | 0.31 | 0.27 | 0.34 | 0.38 | 0.45 | Current Ratio(x) | 1.89 | 1.67 | 1.52 | 1.22 | 1.20 | Quick Ratio(x) | 1.13 | 1.07 | 0.94 | 0.77 | 0.79 | Interest Cover(x) | 8.58 | 14.55 | 6.91 | 2.09 | 0.56 | Total Debt/Mcap(x) | 0.10 | 0.07 | 0.10 | 0.14 | 0.16 |
|
|
|
|
|
|